Join
Live feed
·
PRReleasevia Quantisnow
Zentalis Pharmaceuticals Inc. logo

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

ByQuantisnow·Wall Street's wire, on your screen.
ZNTL· Zentalis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZNTL (Zentalis Pharmaceuticals Inc.) and more on Quantisnow.